Ispire targets cost cuts and manufacturing growth amid nicotine industry shift

Strategic Shift and Financial Progress

Ispire Technology Inc. (ISPR) has made significant strides in its financial foundation and strategic direction during the first quarter of fiscal 2026. Co-CEO and President of Aspire North America, Michael Wang, emphasized the company’s progress in positioning itself for sustainable and profitable growth. A key focus of this strategy is a deliberate shift away from the cannabis industry toward higher-value nicotine sector customers.

Wang highlighted several improvements in financial performance, including a 39% reduction in operating expenses year-over-year, which dropped from $12.9 million to $7.8 million. Net accounts receivable also improved significantly, decreasing from $62.4 million to $44.5 million. The net loss was reduced from $5.6 million to $3.3 million, attributed to the company's focus on cost controls and disciplined expense management.

Operational Advancements

The company has made notable progress with its IKE Tech joint venture, particularly in developing blockchain-based age verification technology. This innovation is being explored in collaboration with regulators in Europe, Southeast Asia, and the Middle East, aiming to set new industry standards. Discussions are ongoing with large and medium-sized nicotine companies regarding proprietary G-Mesh technology, with expectations for new partnerships or licensing agreements in the coming months.

Additionally, the manufacturing facility build-out in Malaysia is advancing rapidly, with plans to expand from 6 to 80 production lines at full capacity. Wang reiterated the company’s commitment to creating a sustainable and profitable business, emphasizing its technological innovations as a foundation for future growth.

Financial Results Overview

CFO Jie Yu reported total revenue for the first quarter of fiscal 2026 at $30.4 million, a decrease from $39.3 million in the same period of fiscal 2025. This decline was primarily due to the company’s shift away from cannabis customers. Gross profit for the quarter was $5.1 million, compared to $7.7 million in the prior year, with gross margins at 17% versus 19.5%. Operating expenses decreased to $7.8 million from $12.9 million, and the net loss improved to $3.3 million from $5.6 million.

As of September 30, 2025, Ispire held $22.7 million in cash. Net cash flow used by operating activities was $1.2 million, and net cash used in investing activities was $540,000. Non-GAAP EBITDA reached $600,000 for the quarter.

Outlook and Future Goals

Wang expressed confidence that the trend of cost reduction, improved profit and loss, and strengthened cash flow will continue through fiscal 2026. The company aims to secure new partnerships and licensing agreements for its G-Mesh technology while ramping up production at the upgraded Malaysian facility throughout the year. This aligns with the strategic shift toward nicotine and ODM customers.

Q&A Highlights

During the earnings call, analysts raised several questions about the company’s strategy and operations. Nicholas Anderson of ROTH Capital Partners asked about the opportunity to onboard clients as JUUL agreements expire. Wang responded by highlighting the company’s proprietary technology and patents, expressing confidence in their approach when engaging with potential nicotine partners.

Anderson also inquired about the timing for receiving a permanent Malaysian license. Wang stated that meeting safety and compliance requirements is the key, and he is confident the license will be received either before the end of the year or around the new year.

Another question focused on the adoption of age-gating technology outside the U.S. Wang noted that some countries may adopt such technology faster than the U.S., indicating potential opportunities in those markets.

Helen Zuanic asked whether Ispire would reconsider focusing on the U.S. cannabis sector given recent developments. Wang reiterated concerns about the industry's ability to make timely payments, stating it remains the company’s top concern.

Zuanic also asked about potential supply chain changes if tariffs are reversed. Wang mentioned that the company is prepared to diversify its supply chain, leveraging existing contract factories in China and its own facilities in Malaysia.

Analyst Sentiment and Market Risks

Analysts generally expressed positive sentiment, congratulating management on the company’s progress and showing interest in strategic growth and regulatory advancements. However, they pressed for more details on licensing, regulatory timelines, and the U.S. cannabis strategy.

Management maintained a confident and optimistic tone, with Wang frequently using phrases like "I am very confident" and "we expect that trend to continue." Compared to previous quarters, the confidence in the nicotine pivot and cost controls remained strong, with analysts’ tone consistent but increasingly interested in near-term licensing and regulatory milestones.

Key Metrics and Risk Factors

Several key metrics showed improvement quarter over quarter, including reductions in operating expenses, net loss, and accounts receivable, alongside a positive non-GAAP EBITDA result.

Management reiterated risks related to the cannabis sector’s cash flow and payment reliability, with Wang noting it as the company’s top concern. The timing and approval of the permanent Malaysian manufacturing license remain a critical operational risk, though management expressed confidence in its resolution.

Regulatory adoption of new technologies and potential shifts in global tariffs also present uncertainties, with management preparing to adjust its supply chain accordingly.

Final Takeaway

Ispire Technology’s Q1 2026 results underscore the company’s intensified strategic pivot toward the nicotine sector, along with disciplined cost reductions and expansion of manufacturing capacity in Malaysia. Leadership emphasized technology innovation, regulatory engagement, and a focus on high-quality customers as the basis for improved financial metrics and optimism for continued progress in fiscal 2026, while remaining cautious about re-engagement with the U.S. cannabis sector until greater financial stability emerges.